23Q/17A repeat: 23 consecutive glutamine residues followed by 17 alanine residues. An insertion of the polyalanine tract (23Q/27A) was previously observed in only one CCD patient [Mundlos et al., 1997] .
Here, we describe a familial case of CCD with a novel mutation within the Q/A domain, which is an insertion of the polyglutamine tract (27Q/17A). In vitro functional analysis was performed to assay the transactivation capacity of the mutant RUNX2 protein.
Case Report
A family with the clinical diagnosis of CCD from the Erciyes University, Turkey, was examined in this study. The proband, a 2-year-old boy, is the only child of an affected father (27 years old) and a healthy mother (23 years old). Radiographs of the proband showed a large defect of the parietal and occipital bones, supernumerary teeth, sclerosis of the cranial base, multiple wormian bones, and bilateral absence of clavicles ( fig. 1 A-C) . The last 2 radiographic manifestations (multiple wormian bones and absent clavicles) were also observed in the boy's father ( fig. 1 D, E) , although he had a relatively thick skull and prognathism ( fig. 1 F) . The craniofacial manifestations, including frontal bossing, midface hypoplasia and a small face, were shared in both the proband and his father.
Methods
After informed consent was obtained from all family members, genomic DNA was extracted from peripheral blood leukocytes. The exons (0-7) and their flanking intronic regions of the RUNX2 gene were amplified by PCR using sets of primers. Direct sequence analysis of the affected patients' DNA from this family demonstrated a novel heterozygous mutation within the Q/A domain, c.213_214insCAGCAGCAGCAG (p.Q71_E72insQQQQ).
For in vitro functional studies of the mutant RUNX2 protein identified in this family, the entire cDNA of p.Q71_E72insQQQQ (27Q) was constructed as follows. We confirmed that the mutation was located between 2 PstI sites (181 bp) in exon 1 and obtained the oligonucleotide duplex containing the mutation (Integrated DNA Technologies MBL, Japan). PCR fragments of the oligonucleotide duplex were double-digested with PstI. This insert was cloned into the human full-length RUNX2 cDNA (Ori-Gene Technologies, Rockville, Md., USA) at the PstI sites. On the other hand, p.T198_T200del (ΔTLT), which was previously identified in a patient with CCD, was constructed by using the QuikChange sitedirected mutagenesis kit (Stratagene, La Jolla, Calif., USA) [Matsushita et al., 2014] . Transient transfection experiments in COS7 cells were performed using FuGENE 6 (Roche, Indianapolis, Ind., USA). Aliquots of 400 ng expression plasmid containing either wild-type or mutagenized RUNX2 were cotransfected with 400 ng of a reporter plasmid p6OSE2-luc (kindly provided by T. Komori, Nagasaki University, Japan) [Harada et al., 1999] . All transfection experiments were done 8 times. The transactivation study showed that the 27Q variant and ΔTLT mutants had significantly lower transcription activities (32 and 61% of the wild type, respectively) ( fig. 2 ).
Discussion
Clinical and radiographic manifestations of the present cases seemed to be typical for CCD, including complete absence of bilateral clavicles, multiple wormian bones and supernumerary teeth. Mutation analysis of this family showed a Q-repeat variant within the Q/A domain, which resulted in a significant reduction of transactivation of the RUNX2 protein.
Q-repeat variants within the RUNX2 gene were identified in an Australian fracture cohort (15Q, 16Q, 24Q, and 30Q) [Vaughan et al., 2002] , a randomly selected population from Aberdeen (16Q) [Vaughan et al., 2004] , and a Spanish population study (16Q, 18Q and 30Q) [Pineda et al., 2010] . A 30Q variant of the RUNX2 gene has never been reported to be associated with CCD phenotypes. On the other hand, a novel 27Q variant caused CCD by downregulating the transactivation activity of the RUNX2 protein. Generally, triplet repeat expansion disorders accelerate their phenotypes according to the repeat length. Huntington's disease, for example, is one of the polyQrepeat disorders, and its severity is usually associated with the length of the polyQ tracts. It has been suggested that aggregation of the polyQ fibers is pathogenic of the disease. Perutz [1996] reported that Huntington's disease has not been observed in individuals with <37 repeats, and absence of disease has never been found in those with >41 repeats. This indicated that polyQ expansion beyond the pathological threshold of 36-40 repeats leads to a clinical manifestation. According to the model of Perutz et al. [2002] , polyQ fibers are composed of nanotubes with 20 residues per turn, and a minimum of 2 turns (40 repeats) is necessary for pathogenic polyQ aggregates. It is possible that the 27Q variant is pathogenic, while the 30Q variant is benign, since the repeat length is not necessarily related to the severity of the disease when it is <40 repeats. Sears et al. [2007] showed that Q/A tandem repeat ratio correlated to RUNX2 transcriptional activity. Morrison et al. [2012] demonstrated that transactivation activity was reduced by the RUNX2 Q-repeat variants, but rescued by PEBP2β, which is the partner subunit for heterodimerization with the Runt domain. In a study on dogs, Fondon and Garner [2004] demonstrated that the length of the Q repeat is significantly associated with midface length and nose curvature. We previously reported a CCD patient with the in-frame deletion (ΔTLT) who showed a milder phenotype than the present cases, including mild short stature (-1.75 SD), delayed fontanelle, midface hypoplasia, pseudoarthrosis of the right clavicle, and hypoplasia of the left clavicle [Matsushita et al., 2014] . ΔTLT mutation decreased the transactivation activity of the RUNX2 protein by abolishing the heterodimerization of the RUNX2 protein with the PEBP2β. Significantly lower transactivation activity of the 27Q variant than that of the ΔTLT mutant may reflect the phenotypic severity of the disease. Transactivation ability of the wild-type and mutant RUNX2 proteins. COS7 cells were transfected with p6OSE2-luc as a reporter plasmid, full-length, wild-type or mutant RUNX2 as effector plasmids, and phRL-TK as an internal control of transfection efficiency. Data are presented as fold activation relative to the activity obtained with wild-type RUNX2 vector plasmid. Bars represent the average ratios of luciferase to Renilla activity. Standard deviations are represented by error bars. Both the 27Q variant and ΔTLT198_200 mutants showed significantly reduced transactivation ability compared to the wild type. Moreover, transactivation of the 27Q variant was significantly lower than that of the ΔTLT198_200 mutant.
